| Literature DB >> 19011396 |
Hui-Hwa Tsai1, Fang-Chi Lin, Shi-Chuan Chang.
Abstract
BACKGROUND: That ventilator-associated pneumonia (VAP) can be reduced by continuous and/or intermittent subglottic suction highlights the importance of clearance of oropharyngeal secretions. We prospectively evaluated the usefulness of intermittent suction of oral secretions before each positional change in reducing VAP.Entities:
Mesh:
Year: 2008 PMID: 19011396 PMCID: PMC7093881 DOI: 10.1097/MAJ.0b013e31816b8761
Source DB: PubMed Journal: Am J Med Sci ISSN: 0002-9629 Impact factor: 2.378
Figure 1Flow diagram of patients in the control (A) and studied (B) groups. ICU, intensive care unit; EI, endotracheal intubation; MV, mechanical ventilation; VAP, ventilator-associated pneumonia.
Demographic and Clinical Data between Control and Studied Groupsa
| Control Group, N = 237 | Studied Group, N = 227 | ||
|---|---|---|---|
| Age, year | 68.1 ± 16.7 | 68.2 ± 16.2 | 0.913 |
| Gender, M/F | 170/67 | 153/74 | 0.311 |
| ICU ward, medical/surgical | 85/152 | 107/120 | 0.014 |
| Smoking, yes/no | 123/114 | 110/117 | 0.516 |
| Admission diagnosis Operation | |||
| Upper abdomen | 110 | 89 | 0.117 |
| Lower abdomen | 12 | 7 | 0.279 |
| Others | 13 | 13 | 0.910 |
| Acute respiratory failure | 14 | 17 | 0.495 |
| Cardiovascular diseases | 15 | 12 | 0.631 |
| Sepsis | 10 | 14 | 0.404 |
| Renal diseases | 8 | 12 | 0.310 |
| Liver diseases | 8 | 11 | 0.424 |
| UGI bleeding | 8 | 9 | 0.736 |
| CNS diseases | 15 | 16 | 0.756 |
| Others | 24 | 27 | 0.543 |
| Risk factors for VAP | |||
| COPD | 15 | 8 | 0.201 |
| DM | 32 | 40 | 0.249 |
| APACHE II score | 28.5 ± 5.9 | 28.1 ± 6.6 | 0.353 |
| Antacid/H2 blockers | 56 | 40 | 0.316 |
| Aerosol therapy | 43 | 24 | 0.372 |
| Corticosteroid | 43 | 51 | 0.251 |
| Sedation | 57 | 46 | 0.372 |
ICU indicates intensive care unit; UGI, upper gastrointestinal; CNS, central nervous system; VAP, ventilator-associated pneumonia; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; APACHE, acute physiology and chronic health evaluation.
Data of mean ± SD or case number are given.
Clinical Outcome between Control and Studied Groupsa
| Control Group, N = 237 | Studied Group, N = 227 | ||
|---|---|---|---|
| Occurrence of VAP | 26 | 6 | <0.001 |
| Ventilator day | 19.0 ± 15.5 | 14.5 ± 11.8 | 0.004 |
| ICU stay, day | 18.2 ± 16.0 | 14.4 ± 11.8 | 0.057 |
| Hospital stay, day | 58.1 ± 58.8 | 58.7 ± 48.0 | 0.675 |
| Mortality | 51 | 40 | 0.290 |
VAP indicates ventilator-associated pneumonia; ICU, intensive care unit.
Data of mean ± SD or case number are given.
Comparisons of Patients with Ventilator-Associated Pneumonia between Control and Studied Groupsa
| Control Group, N = 26 | Studied Group, N = 6 | ||
|---|---|---|---|
| Age, years | 73.2 ± 19.2 | 57.3 ± 26.5 | 0.337 |
| Gender, M/F | 21/5 | 5/1 | 0.883 |
| Ventilator day | 28.8 ± 17.2 | 20.2 ± 4.0 | 0.009 |
| ICU stay, day | 27.6 ± 17.0 | 20.3 ± 4.0 | 0.012 |
| Hospital stay, day | 51.0 ± 34.8 | 60.5 ± 42.5 | 0.558 |
| Mortality | 13 | 1 | 0.121 |
ICU indicates intensive care unit.
Data of mean ± SD or case number are given.
Pathogens of Ventilator-Associated Pneumonia in Control and Studied Groupsa
| Potential Pathogen | Control Group, N = 26 | Studied Group, N = 6 |
|---|---|---|
| No growth | 1 (3.8) | 2 (33.3) |
| 5 (19.2) | 1 (16.7) | |
| 3 (11.5) | 1 (16.7) | |
| 2 (7.5) | ||
| 2 (7.5) | 2 (33.3) | |
| Burkholderia cepacia | 2 (7.5) | |
| 1 (3.8) | ||
| 1 (3.8) | ||
| 1 (3.8) | ||
| ORSA | 1 (3.8) | |
| PDRAB | 1 (3.8) | |
| MDRAB | 1 (3.8) | |
| 1 (3.8) | ||
| MDRAB + | 1 (3.8) | |
| 1 (3.8) | ||
| ORSA + | 1 (3.8) | |
| ORSA + MDRAB | 1 (3.8) |
Values given in parenthesis are percentage.
ORSA indicates oxacillin resistant Staphylococcus aureus; PDRAB, pan-drug resistant Acinetobacter species; MDRAB, multidrug-resistant Acinetobacter species.
The data of case number and (%) are given.